Is RLX Technology (RLX) a Buy Under $2 and Near Net Cash?

TL;DR

• Yes, in size that matches how little coverage this stock gets. RLX closed Friday at $1.94, down 3.0% on the day and near its 52-week low of $1.76.
• The scary headline number is the growth rate: +96.2% revenue in Q1 2026 collapsed to +14.8% in Q2, a 36% sequential drop. Management's own explanation is a shipment pull-forward, not falling demand.
• Non-GAAP net income fell 18.0% year over year even as gross margin expanded from 27.5% to 35.4%, because selling expenses tied to a European acquisition rose 46.1%.
• The number that actually matters: RLX is sitting on roughly $2.0 billion in cash and investments against a $2.37 billion market cap, with next to no debt.
• A 51%-controlling stake in a Western European distributor, bought in July, starts consolidating in Q3 and reaches more than 30,000 retail endpoints RLX didn't have access to before.

Is RLX Technology a Buy Under $2?

Yes. Strip out the cash and the market is pricing the actual operating business, the one growing revenue, expanding into Europe by acquisition, and holding a structurally wider gross margin, at somewhere around $325 million. That is a small number for a company that still did $1.01 billion in RMB revenue (about $148.9 million) in a single quarter that management itself called artificially weak.

I'm not pretending this is a clean story. The headline growth rate cratered, non-GAAP profit went the wrong way, and the company's biggest addressable market, the United States, is still closed to it. But none of those three things are new information the market hasn't already had weeks to price. What's less priced is the balance sheet, and a name this thinly covered is exactly where that kind of gap survives.

The Growth Number That Wasn't Real

RLX Technology, the Shenzhen-based e-cigarette maker that trades in New York as an ADR, posted RMB1,585.8 million in Q1 2026 revenue, up 96.2% year over year and 38.9% quarter over quarter, according to its SEC 6-K filing. That number got the stock a premarket pop back in May.

Q2 came in at RMB1,010.5 million, per the company's own release. Add the two quarters together and you get RMB2,596.3 million, which matches the six-month total the company reported almost to the RMB. So the numbers reconcile: this isn't a restatement or a reporting error, it's a real 36% sequential drop from Q1 to Q2, and the year-over-year growth rate that looked like 96% three months ago is now 14.8%.

Management's explanation, from the Q2 call: "revenue and gross profit moderated sequentially, not due to any softening in demand, but rather reflecting a trade inventory normalization following the first quarter's shipment pull forward driven by regulatory export adjustments." They didn't name the regulation. China ended the VAT export rebate on nicotine inhalation products effective April 1, 2026, a change the trade press had flagged months in advance and one that gave every exporter a reason to ship early. The timing lines up. I can't confirm RLX said so directly, and the company never named the rebate in the filing or the call, so I'm flagging this as the likely mechanism rather than a fact the company confirmed.

Either way, a distributor stocking up ahead of a cost increase and then working through that inventory is a different story than demand falling off. It also means neither the 96% nor the 14.8% number is a clean read on the underlying trend. The truer number is probably somewhere between the two, and the market reacted to Q2 as if it were the second one.

Chinese export and trade policy landing on a stock's numbers with a lag isn't unique to RLX. It's the same basic mechanic behind why Micron trades below $900 on a China-based capacity threat that hasn't shipped a wafer yet: a policy announced months out reshapes near-term order flow long before it shows up in a headline.

Where the Margin Gains Actually Went

Gross margin expanded hard, from 27.5% in Q2 2025 to 35.4% this quarter, and gross profit rose 47.8% year over year to RMB357.8 million. On its own that reads like a much stronger quarter than the revenue line suggests.

It didn't reach the bottom line. Non-GAAP net income fell 18.0% year over year, to RMB238.8 million from RMB291.2 million, because selling expenses jumped 46.1% to RMB123.7 million. The company attributes that to salary, branding, and amortization tied to the European e-vapor business it bought in May 2025, plus a drop in investment income from RMB24.8 million to RMB7.1 million. G&A and R&D both fell on lower stock-based comp, which is the one line item working in the company's favor.

CFO Chao Lu was upfront on the call that the margin number itself won't hold: a downstream distribution business, which is what the new European acquisition is, runs at lower gross margin than RLX's core device and pod sales. Once that business consolidates starting in Q3, the 35.4% print should come down as the mix shifts toward the lower-margin distribution revenue. Nothing about the underlying business breaks when that happens. Anyone reading this quarter's margin line as the new normal is reading it wrong, and the company said so itself.

The Balance Sheet Nobody's Pricing

Here's the part that made this worth writing about. As of June 30, RLX held RMB13,883.4 million in cash and investments, down from RMB14,529.7 million at the end of Q1 (dividends were paid out over that stretch; a dividend payable balance of RMB478.8 million at the end of 2025 was zero by June 30). At the company's own reporting exchange rate, that's roughly $2.0 billion in cash sitting against total liabilities of RMB1,225.0 million, of which only RMB165.2 million is short-term debt and none is long-term. That's a net cash position by any reasonable definition.

Market cap at Friday's close was $2.37 billion. Subtract the cash and the operating business, the one with 68.5% of revenue coming from international markets, a European rollup underway, and a device franchise that's been profitable every year since the IPO, gets valued at something like $325 million. I checked this arithmetic twice because it's the kind of number that sounds too clean. It isn't precise to the dollar, since I'm using the company's own quarterly FX conversion and a market cap pulled after the Friday close, but the gap is wide enough that no rounding error closes it.

A stock priced close to its cash isn't automatically cheap. Markets do this to companies for reasons: a shrinking core business, capital that never comes back to shareholders, or a jurisdiction discount that never closes. RLX has elements of the third one, less of the first two, which is the actual argument for it.

What Keeps This Small

The United States, RLX's largest addressable market by population and disposable income, is effectively closed. The company still needs FDA premarket tobacco authorization to sell there, and on the Q2 call management called the US "uncertain pending regulatory clarity on PMTA applications." That has been true for years and there's no sign it changes soon.

Domestic China sales are guided flat for the year on what the company called conservative approval timelines from regulators there too. So both of RLX's largest potential markets are constrained by the same kind of thing: a regulator that hasn't said no, but hasn't said yes either.

Coverage is thin enough that data providers can't agree on how thin, the same problem that shows up whenever a thinly traded Chinese NYSE listing has almost no US analyst following it. Investing.com lists four analysts on the stock; other trackers show as few as one. Where a target exists, it clusters near $2.90 to $3.00, which would be meaningful upside from $1.94, but I wouldn't lean on that number, because a consensus built from one to four analysts on a sub-$2 ADR isn't a consensus in any useful sense. Price discovery here is mostly retail and momentum, which is a reasonable part of why a company holding close to its own market cap in cash still trades at a 3% single-day drop on a headline growth number.

There's also the plain liquidity risk of a sub-$2 stock: wide percentage spreads, thin daily dollar volume relative to the balance sheet, and a share price low enough that some funds simply won't hold it on mandate. None of that shows up in the income statement. All of it shows up in how the stock trades.

An options structure doesn't fix any of this. At $1.94 a share, a single contract controls about $194 of stock, strikes are priced in nickels, and the relative bid-ask spread on that kind of premium usually eats more of the position than the thesis is worth expressing. I'm not logging a play here. This is a call on the shares or nothing.

The One-Line Read

RLX's growth number scared the market more than the balance sheet reassured it, and a company holding close to its own market cap in cash is where I'd rather be wrong on the cheap side.